Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2003

View Archived Issues

Anticytomegalovirus pyridazinones identified by Bayer researchers

New 5-HT1A receptor ligands discovered at Lundbeck

Aventis claims new KDR inhibitors obtained from natural source

New glucokinase activators under study at AstraZeneca

Novel antidiabetic agents identified at Dr. Reddy's Research Foundation

Advances in Alizyme product development portfolio

No effects on cerebral blood perfusion reported for pravastatin after acute stroke

Eptacog alfa in intracerebral hemorrhage

French team presents novel histamine H3 antagonists

8-Arylquinolines with PDE4-inhibitory activity in Merck pipeline

Neurocrine Biosciences reviews year of significant milestones

Midpoint enrollment reached in Oxytrex study

Progress at Myriad Genetics during second quarter of fiscal 2003

Isis achieves second milestone in Amgen antisense collaboration

Echelon Biosciences awarded grant for cancer and diabetes research

Encouraging results reported for Ontak in steroid-resistant acute GvHD

Phase II trial begins for ISS therapy for asthma

AMD-070 demonstrates promise as a new anti-HIV drug targeting CXCR4

Lorus Therapeutics and NCI to evaluate GTI-2040 in phase II trials

Phase II interim results for GI7DT plus chemotherapy in gastric cancer

Orally available CCR5 antagonist with promise as an anti-HIV candidate

Johnson & Johnson completes acquisition of OraPharma

Debiopharm forms collaboration with Tulane University

Clinically relevant therapeutic window seen for NXY-059 in primate acute stroke model

ImmunoGen highlights key advances in its product pipeline

New data for tenofovir DF plus lamivudine and efavirenz in antiretroviral-naive HIV patients

Evidence of antiretroviral efficacy reported for T-1249 in enfuvirtide-resistant HIV patients

Improved safety and pharmacokinetic profile reported for TMC-114 when combined with ritonavir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....